Long-lasting analgesia via targeted in vivo epigenetic repression
JP2025084803A5Pending Publication Date: 2025-10-06RGT UNIV OF CALIFORNIA
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025023769
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-07-23
- Filing Date
- 2025-02-17
- Publication Date
- 2025-10-06
AI Technical Summary
Technical Problem
Current treatments for chronic pain, particularly those involving narcotic substances, often come with side effects and a significant risk of addiction, and there is a lack of effective, sustainable, and non-addictive therapies.
Method used
The use of a recombinant gene silencing factor complex comprising a dCas9 protein fused to a transcriptional repressor, associated with a guide RNA, to specifically inhibit the expression of genes associated with pain perception, such as TRPV1/2/3/4 and SCN9A, in a targeted and reversible manner.
Benefits of technology
This approach effectively reduces chronic pain in subjects by inhibiting key pain-related gene products, offering a non-addictive and sustainable solution with minimal side effects.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide epigenetic based approaches and methods for use in the treatment or control of chronic pain in subjects.SOLUTION: The present invention provides a method for treating subjects having pain, using constructs comprising a zinc finger (ZF) fused with a repressor domain and / or a dCas9 fused with a repressor domain. This epigenetic approach enables transient gene therapy advantageous in the chronic pain framework, since permanent pain insensitivity is not desired.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art